Epilepsy

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 15, 2021.

The FDA breakthrough device designation follows a pilot study where patients showed a 44% median reduction in seizures when treated with Neuroelectrics’ transcranial electrical stimulation platform.

Joseph Sullivan, MD, provides an overview of the recent approval of fenfluramine oral solution for the treatment of Dravet syndrome.

Elaine C. Wirrell, MD, provides an overview of cannabidiol oral solution for treatment of seizures associated with Dravet syndrome.

Here's what is coming soon to NeurologyLive.

Fabio Nascimento, MD, clinical fellow at Massachusetts General Hospital, spoke about his research on the alarming lack of knowledge on SUDEP and its risk factors among trainees.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 9, 2021.

The clinical fellow at Massachusetts General Hospital discussed whether SUDEP knowledge is at an appropriate level for neurologists and those in other neurology subspecialties.

Joseph Sullivan, MD, and Elaine C. Wirrell, MD, discuss the management of seizures for Dravet syndrome with different approved therapies.

Experts discuss the goals of treatment of patients with Dravet syndrome regarding seizure freedom and seizure burden.

Elaine Wirrell, MD, reviews the transition of care into adulthood of patients with Dravet syndrome and how this transition can affect the patient, caregiver, and care provider.

The panel discusses the impact on the family, siblings, or caregivers of patients with Dravet syndrome.

Here's what is coming soon to NeurologyLive.

Maromi Nei, MD, and Michael R. Sperling, MD, shared their insight on the novel inventory tool for predicting sudden unexpected death in epilepsy and their recently published work.

Neurology News Network for the week ending July 2, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 2, 2021.

The grant will fund a new study to evaluate the effectiveness of brain-responsive neuromodulation in patients with LGS. The study is expected to begin accepting patients in the second half of 2022.

The SUDEP-3 outperformed the prior SUDEP-7 variation on all measures, and simplifies the risk assessment with a 3-item weighted scoring while enhancing the clinical practicality.

Considerations of genetic testing regarding family planning as well as behavioral issues associated with Dravet syndrome.

The clinical fellow at Massachusetts General Hospital discussed his approach to highlighting flaws within the medical education system and the need to do so for certain areas in epilepsy.

Elaine C. Wirrell, MD, explains the increased risk of sudden unexpected death in epilepsy (SUDEP) in patients with Dravet syndrome and how to talk about it with caregivers and families.

An excellent epilepsy outcome was achieved in 66% of cases over a median follow-up of 41 months and was not significantly associated with the type of surgery undergone.

Here's what is coming soon to NeurologyLive.

We kindly ask you to share 5 minutes of your time with us in order to help us better understand how you use social media and how we can better serve you across different platforms.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 25, 2021.